Last viewed:
AXSM
Prices are updated after-hours
AXSM
|
$73.08
2.79%
2.68%
700K
|
Health Technology
(0.0% 1d)
(-5.5% 1m)
(2.6% 1y)
(0.0% 2d)
(2.8% 3d)
(11.2% 7d)
(40.95%
volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 3,462,119,325
http://www.axsome.com
Sec
Filling
|
Patents
| 45 employees
(US) Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
nervous system
add to watch list
Paper trade
email alert is off
Press-releases
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-15
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$73.08
2.79%
2.68%
700K
|
Health Technology
| 2.74%
| O: -3.37%
H: 0.83%
C: -0.76%
neurology
meeting
therapeutics
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Published: 2024-04-10
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$73.08
2.79%
2.68%
700K
|
Health Technology
| 0.61%
| O: -2.66%
H: 1.26%
C: 0.37%
first
report
therapeutics
financial
results
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Published: 2024-04-01
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$73.08
2.79%
2.68%
700K
|
Health Technology
| -8.13%
| O: 0.32%
H: 0.0%
C: -3.52%
treatment
trial
therapeutics
solriamfetol
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Published: 2024-03-25
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$73.08
2.79%
2.68%
700K
|
Health Technology
| -9.4%
| O: 3.64%
H: 0.35%
C: -7.48%
narcolepsy
therapeutics
results
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Published: 2024-03-25
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$73.08
2.79%
2.68%
700K
|
Health Technology
| -9.4%
| O: 3.64%
H: 0.35%
C: -7.48%
axs-12
narcolepsy
symphony
trial
therapeutics
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published: 2024-03-19
(Crawled : 11:00)
- globenewswire.com
AXSM
|
$73.08
2.79%
2.68%
700K
|
Health Technology
| 0.74%
| O: 0.84%
H: 5.95%
C: 5.09%
treatment
trial
therapeutics
solriamfetol
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Published: 2024-03-05
(Crawled : 12:00)
- globenewswire.com
AXSM
|
$73.08
2.79%
2.68%
700K
|
Health Technology
| -6.55%
| O: -0.45%
H: 0.86%
C: -1.58%
conference
biopharma
global
therapeutics
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Published: 2024-02-27
(Crawled : 12:00)
- globenewswire.com
AXSM
|
$73.08
2.79%
2.68%
700K
|
Health Technology
| -11.2%
| O: 0.75%
H: 2.12%
C: 1.3%
conference
therapeutics
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-02-20
(Crawled : 12:00)
- globenewswire.com
AXSM
|
$73.08
2.79%
2.68%
700K
|
Health Technology
| -21.26%
| O: -8.42%
H: 3.52%
C: -4.54%
business
year
update
therapeutics
financial
results
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
Published: 2024-01-23
(Crawled : 12:00)
- globenewswire.com
AXSM
|
$73.08
2.79%
2.68%
700K
|
Health Technology
| -19.62%
| O: 0.62%
H: 0.43%
C: -2.14%
report
year
therapeutics
financial
results
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0000950170-24-039617
4
2024-04-01
2024-04-01
Sell
M
24662
0
0000950170-24-039617
4
2024-04-01
2024-04-01
Sell
S
24662
0
0000950170-24-039617
4
2024-04-01
2024-04-01
Buy
M
24662
24662